Alerta

METHODS AND COMPOSITIONS FOR TRANSDUCING AND EXPANDING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF

Absstract of: MX2026010197A

The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.

1,3,4-THIADIAZOL-2-YL CARBOXAMIDE AND 1,3-THIAZOL-2-YL CARBOXAMIDE COMPOUNDS AND USES THEREOF AS INHIBITORS OF HUMAN POLYMERASE THETA

Absstract of: US20260294921A1

0000 The present application discloses specific compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I), and their use in therapy, in particular, their use as human polymerase theta (Polθ) inhibitors for the treatment of hyperproliferative diseases including cancers such as carcinoma, sarcoma, adenocarcinoma, leukemia, lymphoma, and melanoma, and pre-malignant conditions. The application further discloses the use of a compound of formula (I), in combination with an additional anticancer therapy. 0000

IMMUNOTHERAPEUTICS BASED ON MAGEA1-DERIVED EPITOPES

Absstract of: US20260297156A1

0000 The present invention relates to the field of immunotherapy, in particular, adoptive T cell therapy of MAGEA1-associated cancer. TCR alpha chain constructs (TRA) and/or a TCR beta chain constructs (TRB) of TCR constructs specific for an epitope in complex with a human MHC-I, wherein the epitope is an epitope of a MAGEA1 protein, nucleic acids encoding them and host cells expressing them. The invention also provides pharmaceutical compositions or kits based theron. The invention teaches combinations of TCR constructs directed to different epitopes from the same antigen expressed by the same cancer or infectious agent capabel of being presented by different MHC-I molecules, wherein optionally, the antigen is MAGEA1. Preferably, at least one of the TCR constructs used in the combination is a TCR construct of the invention disclosed herein. The pharmaceutical combinations or kits may be used for immunotherapy of a subject, e.g., adoptive T cell therapy or TCR gene therapy, e.g., for use in treatment of a cancer such as lung cancer, colorectal cancer, or multiple myeloma. The invention also provides peptides comprising the epitopes recognized by the TCR constructs of the invention, which may be for use in vaccination, e.g., peptide vaccination or RNA vaccination.

MULTIPLE MYELOMA TREATMENT

Absstract of: US20260294848A1

0000 The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).

HYDROXYLAMINE-BASED BCR-ABL1 INHIBITORS FOR TREATMENT OF CANCER

Absstract of: US20260297031A1

0000 In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to scaffold molecules that inhibit breakpoint cluster region, chromosome 22 (BCR) and Abelson proto-oncogene 1, chromosome 9 (ABL1) in a subject, methods of making same, pharmaceutical compositions comprising same, and methods of treating cancers involving aberrant BCR and ABL1 activity. In another aspect, the compounds described herein can evade P-gp-mediated efflux in a subject, which makes the compounds effective in treating a Philadelphia chromosome positive (Ph+) leukemia.

KAT6A, KAT6B, AND KAT7 INHIBITORS AND USES THEREOF

Absstract of: WO2026202706A1

The present invention provides compounds of Formula I:, I which are useful for the inhibition of KAT6A, KAT6B, and/or KAT7. Compounds of Formula I are useful for the treatment of cancer, including bladder cancer, breast cancer, cervical cancer, colorectal cancer including colon and rectal adenocarcinomas, leukemias including acute myeloid leukemia (AML), lung adenocarcinoma, medulloblastoma, osteosarcoma, ovarian cancer, and prostate cancer.

MENIN-MLL INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF

Absstract of: WO2026200437A1

Disclosed in the present invention are a Menin-MLL inhibitor, a preparation method therefor and the use thereof. The inhibitor can be used for the treatment of related diseases (in particular, hematological tumors (such as leukemia) and diabetes), and has excellent application prospects and research value.

COMPOSITIONS COMPRISING FLUDARABINE PHOSPHATE AND METHODS OF MAKING AND USING SAME TO TREAT CANCER

Absstract of: US20260294951A1

0000 The present disclosure provides compositions (e.g., injectable compositions) comprising fludarabine (e.g., fludarabine phosphate), and methods of using same to treat cancers, such as a lymphoma, and/or to lymphodeplete a subject in need thereof, for example in association with a CAR-T therapeutic regimen.

Keratin YK93-2, and Preparation Method Therefor, Pharmaceutical Composition Thereof and Use Thereof

Absstract of: US20260297147A1

The present invention belongs to the field of biopharmaceuticals. Provided are a keratin YK93-2, a nucleic acid molecule encoding the same, an expression vector including the nucleic acid molecule, a host cell including the expression vector or the genome integrated with the nucleic acid molecule, a preparation method therefor and a pharmaceutical composition thereof. Further provided is the use of the above-mentioned product, such as keratin YK93-2 in the preparation of a drug for treating lung cancer, lymphoma, breast cancer, melanoma, uterine fibroid, prostatic hyperplasia etc.

COMPOSITIONS OF MRNA-ENCODED VIRUS-LIKE PARTICLES, COMPOSITIONS OF MRNA-LIPID NANOPARTICLES, AND METHODS FOR USE THEREOF

Absstract of: US20260295033A1

An immunogenic composition is described, comprising mRNA encoding polypeptides constituting a virus-like particle (VLP), and a pharmaceutically acceptable carrier. The polypeptides constituting the VLP comprise: a first polypeptide comprising a gag protein found in murine leukemia virus (MEV) having at least 95% identity with the amino acid sequence of SEQ ID NO: 1; and at least one additional polypeptide, which may comprise a protein of a virus, such as EB V, CMV, or coronavirus, for example a spike glycoprotein from a beta coronavirus such as SARS-COV-2, SARS-COV-1 or MERS-COV; or the at least one additional polypeptide may comprise a protein expressed by a cancer cell or tumour cell. A lipid nanoparticle composition is also described, which may comprise the VLPs. Methods of treatment or prevention of infection, such as from EBV, CMV, or coronavirus, or for treatment or prevention of cancer are described.

ANTI-B-CELL MATURATION ANTIGEN (BCMA) BINDING DOMAINS AND USES THEREOF

Absstract of: WO2026207156A1

Anti-B-cell maturation antigen (BCMA) binding domains and uses thereof are provided. The binding domains can be used to target such cells expressing BCMA ex vivo or in vivo for research, diagnostic, or therapeutic purposes, for example in the treatment of multiple myeloma.

Keratin YK93-5, Preparation Method, and Pharmaceutical Composition and Use Thereof

Absstract of: US20260297148A1

The present invention relates to the field of biological pharmacy, provides keratin YK93-5, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or a genome integrated with the nucleic acid molecule, a preparation method for the keratin YK93-5, and a pharmaceutical composition of the keratin YK93-5, and further provides a use of the products such as the keratin YK93-5 in the preparation of drugs for treating lung cancer, lymphoma, breast cancer, melanoma, uterine fibroids, prostatic hyperplasia, etc.

CARS AND CAR-NK CELLS TARGETING BOTH BCMA AND GPRC5D AND USE THEREOF IN TREATING MULTIPLE MYELOMA

Absstract of: WO2025108429A1

A chimeric antigen receptors (CARs) and CAR-NK cells targeting both BCMA and GPRC5D and use thereof in treating multiple myeloma (MM) is provided. In particular, the disclosure relates to bi-specific CARs comprising: (a) a B-cell maturation antigen (BCMA) targeting domain; and (b) a G protein-coupled receptor of family C, group 5, member D (GPRC5D) targeting domain, preferably armored with such as IL15, and the corresponding coding polynucleotides for the CARs and vectors comprising the polynucleotides. Also provided is CAR-NK cell modified with the CAR (s), and use of the CAR and CAR-NK cell in the treatment of MM.

EDELFOSINE FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA

Absstract of: EP4813380A1

The present invention relates to the use of the alkyl phospholipid edelfosine (especially (S)-edelfosine) in the treatment of multiple myeloma.

BISPECIFIC CD33 AND CD3 BINDING PROTEINS

Nº publicación: EP4813396A2 30/09/2026

Applicant:

AMPHIVENA THERAPEUTICS INC [US]
Amphivena Therapeutics, Inc.

Absstract of: EP4813396A2

Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33⁺ cancers, diseases and conditions such as acute myeloid leukemia (AML).